ALS News Today Home | ALS News Today
WEB4 days ago · Amprion wins $100K to study causes of sporadic ALS. Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and …
FDA Approves First ALS Treatment Via Accelerated Approval
WEBApr 25, 2023 · ALS Association Funded Antisense Technology Behind Tofersen. Washington, D.C. (April 25. 2023) – The ALS Association commends the FDA for approving tofersen under the agency’s accelerated approval pathway for the treatment of people living with ALS connected to mutations in the SOD1 gene.
A “Game-Changer” – Groundbreaking Discovery Paves Way for ALS …
WEBMay 29, 2024 · In a groundbreaking Canadian discovery powered by philanthropy, a team of Western University researchers led by Dr. Michael Strong has uncovered a potential path toward a cure for amyotrophic lateral sclerosis (ALS).
Scientists may have discovered a potential cure for ALS - The Toronto Star
WEBMay 17, 2024 · A team of researchers at Western University have made a major breakthrough that could pave the way to a cure for amyotrophic lateral sclerosis (ALS) — a devastating nervous system disease that...
Amyotrophic Lateral Sclerosis News -- ScienceDaily
WEBMar 13, 2024 · Latest research news on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, including experimental treatments.
FDA final approval decision on NurOwn for ALS due by year’s end
WEBJun 8, 2023 · A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now expected no later than Dec. 8.
Hotly anticipated ALS drug could pave way for more brain
WEBApr 17, 2023 · The US Food and Drug Administration (FDA) is set to rule soon on the approval of a new drug for a rare form of amyotrophic lateral sclerosis (ALS). The hotly anticipated decision is expected to...
Phase 1 clinical trial of experimental ALS therapy ... - ALS News …
WEBAug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).
FDA Approves ALS Treatment Despite Questions About ... - The New York Times
WEBSep 29, 2022 · The Food and Drug Administration on Thursday approved an experimental treatment for A.L.S., a severe neurological disorder that causes paralysis and death, despite questions about the...
In reversal, FDA panel votes to recommend experimental ALS drug - NBC News
WEBSep 7, 2022 · A Food and Drug Administration advisory panel voted Wednesday to recommend an experimental drug for patients with ALS, a reversal from its decision in March and a victory for advocacy groups ...
Skip to content